Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QBX258 (VAK694 + QAX576) in inadequately controlled asthma
2011-003066-32Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing QBX258 (VAK694 + QAX576) with Placebo (2 arms). Primary endpoint: Change in Asthma Control Questionnaire score. Started Sep 2011; status: completed.
02
Drugs
QBX258
03
Conditions
asthma
Beyond the preview
Go deeper on 2011-003066-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003066-32.